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Abstract
IMPORTANCE Chronic kidney disease (CKD) is serious and common, yet recognition and public
health responses are limited.
OBJECTIVE To describe clinical features of, prevalence of, major risk factors for, and care for CKD
among patients treated in 2 large US health care systems.
DESIGN, SETTING, AND PARTICIPANTS This cohort study collected data from the Center for
Kidney Disease Research, Education, and Hope (CURE-CKD) registry, an electronic health record–
based registry jointly curated and sponsored by Providence St Joseph Health and the University of
California, Los Angeles. Patients were adults and children with CKD (excluding end-stage kidney
disease) and adults at risk of CKD (ie, with diabetes, hypertension, or prediabetes) identified by
laboratory values, vital signs, prescriptions, and administrative codes. Data were collected from
January 2006 through December 2017, with analyses performed fromMarch 2019 through
November 2019.
EXPOSURES Diabetes, hypertension, and prediabetes.
MAINOUTCOMESANDMEASURES Clinical and demographic characteristics, prevalence, and
prescribedmedications.
RESULTS Of 2 625 963 adults and children in the sample, 606064 adults (23.1%) with CKD had a
median (interquartile range [IQR]) age of 70 (59-81) years, with 338 785 women (55.9%) and
434 474 non-Latino white individuals (71.7%). A total of 12 591 children (0.4%) with CKD had a
median (IQR) age of 6 (1-13) years, with 7079 girls (56.2%) and 6653 non-Latino white children
(52.8%). Median (IQR) estimated glomerular filtration rate was 53 (41-61) mL/min/1.73 m2 among
adults and 70 (50-95) mL/min/1.73 m2 in children. Prevalence rates for CKD in adults were 4.8%
overall (606064 of 12 669 700) with 1.6% (93 644 of 6011 129) during 2006 to 2009, 5.7%
(393 455 of 6 903084) during 2010 to 2013, and 8.4% (683 574 of 8 179 860) during 2014 to 2017
(P < .001). A total of 226 693 patients (37.4%) had category 3a CKD; 100 239 (16.5%), category 3b
CKD; 39 125 (6.5%), category 4 CKD; and 20 328 (3.4%), category 5 CKD. Among adults with CKD,
albuminuria and proteinuria assessments were available in 52 551 (8.7%) and 25035 (4.1%) patients,
respectively. A renin-angiotensin system inhibitor was prescribed to 124 575 patients (20.6%), and
204 307 (33.7%) received nonsteroidal anti-inflammatory drugs or proton pump inhibitors. Of
1 973 258 adults (75.1%) at risk, one-quarter had diabetes or prediabetes (512 299 [26.0%]), nearly
half had hypertension (955 812 [48.4%]), and one-quarter had both hypertension and diabetes or
prediabetes (505 147 [25.6%]).
(continued)
Key Points
Question What are the clinical
characteristics of andmajor risk factors
for chronic kidney disease among
patients in 2 large US health
care systems?
Findings In this cohort study of the
Center for Kidney Research, Education,
and Hope (CURE-CKD) registry, more
than 2.6million adults and children had
chronic kidney disease or were at risk.
Albuminuria or proteinuria was tested in
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Meaning Despite common occurrence
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identification and use of kidney
protective agents were low, while use of
potential nephrotoxinswaswidespread.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE This registry-based cohort study revealed a burgeoning number
of patients with CKD and its major risk factors. Rates of identification and use of kidney protective
agents were low, while potential nephrotoxin use was widespread, underscoring the pressing need
for practice-based improvements in CKD prevention, recognition, and treatment.
JAMA Network Open. 2019;2(12):e1918169. doi:10.1001/jamanetworkopen.2019.18169
Introduction
Chronic kidney disease (CKD) is a serious and common disease, and it eventuates in multiple
complications, including premature mortality and end-stage kidney disease (ESKD).1-3 An estimated
1 in 7 to 10 adults worldwide have CKD,with only approximately 10% surviving to ESKD and only half
of survivors receiving dialysis or a kidney transplant because of lack of access or high costs.3 From
1990 to 2016, the prevalence of CKD increased by 90%, and related deaths, mainly due to
cardiovascular diseases and infections, nearly doubled in the United States and globally.4-6 In high-
income countries, 2% to 3% of annual health care costs are devoted to the 0.03% of the population
with ESKD.7
The increasing prevalence of CKD is closely tied to the increase of at-risk populations with
diabetes, hypertension, and prediabetes. Indeed, diabetes is the leading cause of CKD and a global
health emergency, with 425 million individuals affected worldwide in 2017 and a projected 629
million individuals affected by 2045.8-10 Hypertension is the secondmost frequent cause of CKD,
affecting nearly one-third of US adults and 1.13 billion people globally in 2015.11,12 The estimated
population size for prediabetes was 78.5million among adults in the United States between 2011 and
2014, and nearly one-tenth have been reportedwith CKD.13 Even so, awareness of CKD and itsmajor
risk factors remains strikingly low among health care professionals and patients alike.14-16
The Advancing American Kidney Health initiative was recently launched by a US executive order
calling for new approaches to prevent and treat CKD,with a goal of reducing ESKD incidence 25%by
2030.17 Real-world data from electronic health records (EHRs) provide an ideal platform to answer
this call by improving CKD detection, tracking, and public health responses. The Center for Kidney
Disease Research, Education, and Hope (CURE-CKD) registry contains detailed patient-level EHR
data frommore than 2.6 million adults and children with CKD and at risk of CKD during 12 inclusive
years.18 The objective of this study was to describe baseline clinical features of, prevalence of, major
risk factors for, and care for CKD based on data from the CURE-CKD registry.
Methods
The study was approved by Providence St Joseph Health (PSJH; Washington, Montana, Oregon,
Alaska, and California) and the University of California, Los Angeles (UCLA; California) Health
institutional review boards, which determined that written informed consent was not required for
this limited data set. Data use agreements between PSJH and UCLA Health formed the framework
for data sharing, stewardship, and security. This studywas conducted according to the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for
cohort studies.19
StudyDesign
Detailed methodology for CURE-CKD has been previously published.18 The formation of CURE-CKD
was supported by institutional funding from PSJH and UCLA Health. Both health care systems use
Epic EHRs (Epic Systems). The first phase of CURE-CKD created a data repository with patient
information from EHRs with at least 1 measure indicating CKD, diabetes, prediabetes, or
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hypertension based on patient-level laboratory values, vital signs, prescriptionmedications, and
administrative codes from January 1, 2006, to December 31, 2017. Electronic health record data for
these patients were extracted from ambulatory and inpatient encounters. Unstructured data from
the EHRs were not extracted. The total number of patients with encounters and serum creatinine
measures for the health care systemswas also recorded. Repository updates are performed annually.
The second phase crafted an EHR-based registry of participants with CKD and at risk for CKD
derived from the repository. The first 90 days a patient was included in the registry were considered
the baseline period. Registry criteria were based on established clinical practice guidelines for CKD
(eTable 1 in the Supplement). Adults (ie, aged18 years) were included with 2 or more of the
following laboratory measurements recorded at least 90 days apart: estimated glomerular filtration
rate (eGFR) less than 60mL/min/1.73 m2, calculated from serum creatinine levels using the Chronic
Kidney Disease Epidemiology equation; urine albumin to creatinine ratio greater than 30mg/g; and
urine protein to creatinine ratio greater than 150 mg/g.20,21 Children (ie, aged <18 years) with CKD
were identified using the same criteria, except the bedside Schwartz equation was used to calculate
eGFR from serum creatinine levels.22We identified CKD categories 1 and 2 by an administrative code,
urine albumin to creatinine ratio greater than 30mg/g, and/or urine protein to creatinine ratio
greater than 150mg/g. We identified CKD categories 3 to 5 based on eGFR and/or administrative
code. Patients with ESKD treated with dialysis or kidney transplant were excluded. Participants with
diabetes, prediabetes, and hypertensionwere identified by clinical practice guidelines and published
criteria for EHR identification23-25 (eTable 1 in the Supplement).
Statistical Analysis
Data analyses were performed fromMarch 2019 through November 2019. Continuous variables are
reported as mean and SD or as median and interquartile range (IQR) for skewed or kurtotic
distributions. Categorical variables are reported as frequencies and percentages. The Pearson χ2 test
for independencewas used to determine differences between categorical variables. Prevalence rates
for CKD among adults are presented as a combined data set fromPSJH andUCLAHealth and by each
system. To address sources of bias in CKD prevalence rates, datawere analyzed as proportions based
on the 3 following definitions for CKD: (1) CURE-CKD entry criteria, (2) 2measurements of eGFR less
than 60mL/min/1.73m2 at least 90 days apart; and (3) 1 measurement of eGFR less than 60mL/min/
1.73m2. Serial prevalence rates of CKD overall, by categories, and prescriptionmedication use during
3 periods (ie, 2006-2009, 2010-2013, and 2014-2017) were analyzed by logistic regressionmodels.
Prevalence was adjusted for age, sex, and race/ethnicity in the models using repository data (ie, CKD
by 1 or 2 eGFRmeasurements). Adjustments could not bemade for CKD prevalence with the
denominator based on the total number of patients with encounters because the institutional review
board approvals did not include data extraction for age, sex, and race/ethnicity from the total
populations in the health care system.
To reduce risk of type I error, a 2-tailed P < .001 was the a priori threshold for statistical
significance because of the large sample size and resultant high level of statistical power. Because
overall CKD participant characteristics, except distribution of geolocation, were similar between
PSJH and UCLA Health, findings other than prevalence are presented from a jointly curated data set.
Descriptive statistics and the Pearson χ2 test were conducted with SQL Server Management Studio
2012 version 11.0.2100.60 (Microsoft Corp); tests for normality and logistic regression were
completed using SPSS statistical software version 23 (IBM Corp).
Results
Demographic Characteristics in Adults and ChildrenWith CKD andAdults At Risk
of CKD
A total of 2 625 963 adults and children were included in the sample. The cohort of adults with CKD
included 606064 individuals (23.1%), including 338 785 women (55.9%), 434 474 non-Latino white
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individuals (71.7%), 17 625 Latino individuals (2.9%), 29 974 black individuals (4.9%), 32 850 Asian
individuals (5.4%), 5461 American Indian and Alaska Native individuals (0.9%), and 3899 Hawaiian
and Pacific Islander individuals (0.6%) (Table 1). The median (IQR) age among adults was 70 (59-81)
years. The proportions with CKDwere highest among those aged 60 to 89 years (401 541 [66.3%]).
A total of 12 591 children (0.4%) with CKD included 7079 girls (56.2%) and 6653 non-Latino white
children (52.8%) (Table 2). The median (IQR) age of children with CKD was 6 (1-13) years, and CKD
was comparably distributed across age groups (2545 [20.2%] aged <1 year; 2241 [17.8%], 1-3 years;
1515 [12.0%], 4-6 years; 1863 [14.8%], 7-10 years; 1916 [15.2%], 11-14 years; and 2511 [19.9%], 15-17
years). The cohort of participants at risk for CKD included 1 973 258 adults (75.1%). Among them,
955 812 (48.4%) had hypertension alone, while 505 147 (25.6%) had diabetes or prediabetes with
hypertension, and 512 299 (26.0%) had diabetes or prediabetes alone. Those at risk for CKD included
1 014 847 women (51.4%), 1 308036 non-Latino white individuals (66.3%), 60 201 Latino
individuals (3.1%), 92 403 black individuals (4.9%), 114 400 Asian individuals (5.8%), 19 820
American Indian and Alaska Native individuals (1.0%), and 11 420 Hawaiian and Pacific Islander
individuals (0.6%) (eTable 2 in the Supplement). Proportions of participants at risk for CKDwere
highest among those aged 50 to 69 years (866 528 [43.9%]).
Comparing adults with CKDwith those at risk for CKD, womenweremore frequently
represented in the cohort with CKD than in the cohort at risk for CKD (338 785 [55.9%] vs 1 014 847
[51.4%]; P < .001). Non-Latino white individuals (434 474 [71.7%] vs 1 308036 [66.3%]; P < .001)
and individuals aged 70 years or older (315 397 [52.0%] vs 386 364 [19.6%]; P < .001) were also
more common among participants with CKD vs those at risk. Therewas a higher proportionwith rural
geolocation within PSJH vs UCLA Health (287 622 [17.2%] vs 6918 [1.8%]; P < .001).
Clinical Characteristics in Adults and ChildrenWith CKD andAdults at Risk for CKD
A total of 243 635 adults with CKD (40.2%) were identified by eGFR, 163 375 (27.0%) by
administrative codes, and 151 794 (25.0%) by both eGFR and administrative codes. Various
combinations of laboratory measurements and administrative codes accounted for the remainder of
adult CKD identification.More than half of adults with CKDwere in category 3 (3a, 226 693 [37.4%];
3b, 100 239 [16.5%]) (Table 1). Decreases in prevalence were observed for CKD category 4 (39 125
[6.5%]) and category 5, not dialyzed (20 328 [3.4%]). Median (IQR) eGFRwas 53 (41-61) mL/min/1.73
m2, andmeasurements of albuminuria and proteinuria were recorded in 52 511 (8.7%) and 25035
(4.1%) patients, respectively. Mean (SD) systolic and diastolic blood pressure values were 129 (18)
mmHg and 72 (11) mmHg, respectively. When participants with CKD and diabetes or prediabetes
were assessed separately, higher proportions of patients with diabetes than those with prediabetes
had CKD category 4 or 5 (9790 [18.4%] vs 3724 [13.2%]; P < .001), and higher levels of albuminuria
or proteinuria were present in the group with diabetes compared with the group with prediabetes
(5555 [10.4%] vs 965 [3.4%]; P < .001) (eTable 3 in the Supplement).
Most children (10 841 [86.1%]) were identified exclusively through CKD administrative codes.
Among 8145 children (64.7%), CKD was not categorized (Table 2). Median (IQR) eGFR was 70
(50-95) mL/min/1.73 m2. Mean (SD) systolic and diastolic blood pressure were 104 (16) mmHg and
61 (11) mm Hg, respectively. Measurements of albuminuria and proteinuria were available in 520
(4.1%) and 798 (6.4%) children, respectively.
Median (IQR) eGFR in adults at risk of CKD was 90 (77-103) mL/min/1.73 m2, and albuminuria
and proteinuria measurements were recorded in 51 470 (2.6%) and 10 285 (0.5%), respectively
(eTable 2 in the Supplement). Mean (SD) systolic and diastolic blood pressure values were 135 (18)
mmHg and 79 (12) mmHg, respectively. When participants with diabetes or prediabetes who were
at risk for CKDwere analyzed separately, frequency of ascertainment for albuminuria or proteinuria
was 7% or less in all groups (eg, among 317 648 patients with diabetes and hypertension, albumin to
creatine ratiomeasurementswere available for 21 697 patients [6.8%]; among 187 499 patients with
prediabetes and hypertension, protein to creatine ratiomeasurementswere available in 907 [0.5%])
(eTable 4 in the Supplement).
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Table 1. Characteristics of AdultsWith CKD in the CURE-CKD Registry
Characteristic
No. (%)
All CKD
(N = 606 064)
CKD With Diabetes,
Prediabetes,
and Hypertension
(n = 300 157)
CKD With Hypertension
(n = 134 500)
CKD With Diabetes
or Prediabete
s (n = 81 266)
CKD Alone
(n = 90 141)
Demographic
Sex
Men 267 285 (44.1) 142 197 (47.4) 53 703 (39.9) 38 600 (47.5) 32 785 (36.4)
Women 338 755 (55.9) 157 959 (52.6) 80 795 (60.1) 42 657 (52.5) 57 344 (63.6)
Race/ethnicity
Non-Latino white 434 474 (71.7) 217 009 (72.3) 106 538 (79.2) 52 453 (64.5) 58 474 (64.9)
Latino 17 625 (2.9) 8749 (2.9) 2570 (1.9) 3339 (4.1) 2967 (3.3)
Black 29 974 (4.9) 17 856 (5.9) 5742 (4.3) 3466 (4.3) 2910 (3.2)
Asian 32 850 (5.4) 19 566 (6.5) 5036 (3.7) 4533 (5.6) 3715 (4.1)
American Indian or Alaska
Native
5461 (0.9) 2887 (1.0) 1150 (0.9) 630 (0.8) 794 (0.9)
Hawaiian or Pacific Islander 3899 (0.6) 2509 (0.8) 580 (0.4) 411 (0.5) 399 (0.4)
Other 33 152 (5.5) 15 746 (5.1) 5312 (3.9) 5296 (6.5) 6798 (7.5)
Multiple races 163 (0.1) 120 (0.1) 23 (0.1) 5 (0.1) 15 (0.1)
Not reporteda 48 466 (8.0) 15 715 (5.2) 7549 (5.6) 11 133 (13.7) 14 069 (15.6)
Entry age, y
18-39 49 097 (8.1) 11 965 (4.0) 11 389 (8.5) 4797 (5.9) 20 946 (23.2)
40-49 37 544 (6.2) 17 134 (5.7) 7971 (5.9) 4624 (5.7) 7815 (8.7)
50-59 74 616 (12.3) 40 752 (13.6) 14 205 (10.6) 9466 (11.6) 10 193 (11.3)
60-69 129 410 (21.4) 74 535 (24.8) 25 148 (18.7) 16 156 (19.9) 13 571 (15.1)
70-79 144 263 (23.8) 81 043 (27.0) 31 310 (23.3) 18 314 (22.5) 13 596 (15.1)
80-89 127 868 (21.1) 59 896 (20.0) 32 116 (23.9) 20 165 (24.8) 15 691 (17.4)
≥90 43 266 (7.1) 14 832 (4.9) 12 361 (9.2) 7744 (9.5) 8329 (9.2)
Clinical
eGFR CKD category
1-2 137 784 (22.7) 76 605 (25.5) 25 718 (19.1) 15 882 (19.5) 19 579 (21.7)
3a 226 693 (37.4) 112 931 (37.6) 58 757 (43.7) 27 773 (34.2) 27 232 (30.2)
3b 100 239 (16.5) 48 384 (16.1) 21 642 (16.1) 17 197 (21.2) 13 016 (14.4)
4 39 125 (6.5) 18 737 (6.2) 6083 (4.5) 8862 (10.9) 5443 (6.0)
5, Not dialyzed 20 328 (3.4) 10 181 (3.4) 2861 (2.1) 4652 (5.7) 2634 (2.9)
Not categorizedb 81 895 (13.5) 33 319 (11.1) 19 439 (14.5) 6900 (8.5) 22 237 (24.7)
UACR, mg/g
≤30 17 651 (2.9) 12 703 (4.2) 1776 (1.3) 2224 (2.7) 948 (1.1)
>30 to ≤300 27 227 (4.5) 21 435 (7.1) 1089 (0.8) 4066 (5.0) 637 (0.7)
>300 7673 (1.3) 5860 (2.0) 509 (0.4) 995 (1.2) 309 (0.3)
Not measured 553 513 (91.3) 260 159 (86.7) 131 126 (97.5) 73 981 (91.0) 88 247 (97.9)
UPCR, mg/g
≤150 14 467 (2.4) 7823 (2.6) 2723 (2.0) 2076 (2.6) 1845 (2.0)
>150 to ≤500 5688 (0.9) 3087 (1.0) 1163 (0.9) 763 (0.9) 675 (0.7)
>500 4880 (0.8) 2978 (1.0) 785 (0.6) 696 (0.9) 421 (0.5)
Not measured 581 029 (95.9) 286 269 (95.4) 129 829 (96.5) 77 731 (95.7) 87 200 (96.7)
Age, median (IQR) [No.], y 70 (59-81) [606 064] 70 (60-79) [300 157] 72 (60-83) [134 500] 73 (63-83) [81 266] 64 (42-81) [90 141]
eGFR, median (IQR) [No.],
mL/min/1.73 m2
53 (41-61) [524 169] 54 (43-63) [266 838] 53 (44-59) [115 061] 49 (35-59) [74 366] 53 (41-66) [67 904]
SBP, mean (SD) [No.], mm Hg 129 (18) [365 561] 131 (18) [202 951] 132 (18) [92 051] 119 (17) [25 533] 119 (16) [45 026]
DBP, mean (SD) [No.], mm Hg 72 (11) [365 561] 72 (10) [202 951] 74 (11) [92 051] 67 (10) [25 533] 70 (10) [45 026]
Abbreviations: CKD, chronic kidney disease; CURE-CKD, Center for Kidney Disease
Research, Education, and Hope; DBP, diastolic blood pressure; eGFR, estimated
glomerular filtration rate; IQR, interquartile range; SBP, systolic blood pressure; UACR,
urine albumin to creatinine ratio; UPCR, urine protein to creatinine ratio.
a Includes null, unknown, and patient did not report.
b Individuals who were identified by CKD administrative codes only could not be
categorized.
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Table 2. Characteristics of ChildrenWith CKD in the CURE-CKD Registry
Characteristic No. (%) (N = 12 591)
Demographic
Sex
Boys 5511 (43.8)
Girls 7079 (56.2)
Race/ethnicity
Non-Latino white 6653 (52.8)
Latino 952 (7.6)
Black 677 (5.4)
Asian 697 (5.5)
American Indian or Alaska Native 294 (2.3)
Hawaiian or Pacific Islander 152 (1.2)
Other 2060 (16.4)
Multiple races 12 (0.1)
Not reporteda 1094 (8.7)
Entry age, y
<1 2545 (20.2)
1-3 2241 (17.8)
4-6 1515 (12.0)
7-10 1863 (14.8)
11-14 1916 (15.2)
15-17 2511 (19.9)
Clinical
eGFR CKD category
1-2 2514 (20.0)
3a 1145 (9.1)
3b 503 (4.0)
4 191 (1.5)
5, Not dialyzed 93 (0.7)
Not categorizedb 8145 (64.7)
UACR, mg/g
≤30 220 (1.7)
>30 to ≤300 198 (1.6)
>300 102 (0.8)
Not measured 12 071 (95.9)
UPCR, mg/g
≤150 481 (3.8)
>150 to ≤500 158 (1.3)
>500 159 (1.3)
Not measured 11 793 (93.7)
Age, median (IQR) [No.], y 6 (1-13) [12 591]
eGFR, median (IQR) [No.], mL/min/1.73 m2 70 (50-95) [4446]
SBP, mean (SD) [No.], mm Hg 104 (16) [8768]
DBP, mean (SD) [No.], mm Hg 61 (11) [8768]
Abbreviations: CKD, chronic kidney disease; CURE-CKD, Center for Kidney
Disease Research, Education, and Hope; DBP, diastolic blood pressure; eGFR,
estimated glomerular filtration rate; IQR, interquartile range; SBP, systolic blood
pressure; UACR, urine albumin to creatinine ratio; UPCR, urine protein to
creatinine ratio.
a Includes null, unknown, and patient did not report.
b Individuals whowere identified by CKD administrative codes only could not be
categorized.
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Prevalence of and Temporal Trends in CKDAmongAdults
A total of 12 669 700 patients received care at PSJH (10 793 550 [85.2%]) and UCLA Health
(1 876 150 [14.8%]) between January 1, 2006, and December 31, 2017 (eFigure in the Supplement).
During this period, 606064 adults (4.8%) met the CURE-CKD registry entry criteria for CKD.
However, when CKDwas determined by at least 2 eGFRmeasurements of less than 60mL/min/1.73
m2 at least 90 days apart, unadjusted prevalence among adults was 26.1% (420678 of 1 612 737),
and adjusted CKD prevalence was 22.6%. When determined by 1 eGFR measure, unadjusted CKD
prevalence was 34.4% (873 642 of 2 542 393), and adjusted prevalence was 32.9% (Table 3).
Diagnostic coding for CKDwas recorded among 171 011 patients (40.7%) with CKD determined by 2
eGFR measurements at least 90 days apart and among 240630 patients (27.5%) with CKD
determined by 1 eGFRmeasurement.
Table 3. Prevalence of CKDAmong Adults at PSJH and UCLAHealtha
Group 2006-2009 2010-2013 2014-2017 2006-2017
Encounters for CURE-CKD
criteria, No.
PSJH and UCLA Health 6 011 129 6 903 084 8 179 860 12 669 700
PSJH 5 366 296 6 100 530 7 025 762 10 793 550
UCLA Health 644 833 802 554 1 154 098 1 876 150
2 eGFR measures, No.b
PSJH and UCLA Health 288 258 913 177 1 076 536 1 612 737
PSJH 199 789 809 519 895 259 1 356 375
UCLA Health 88 469 103 658 181 277 256 480
1 eGFR measure, No.
PSJH and UCLA Health 577 845 1 500 025 1 893 309 2 542 393
PSJH 430 252 1 320 786 1 582 785 2 115 250
UCLA Health 147 593 179 239 310 524 427 143
CKD by CURE-CKD criteria,
No. (%)
PSJH and UCLA Health 93 644 (1.6) 393 455 (5.7) 683 574 (8.4) 606 064 (4.8)
PSJH 69 332 (1.3) 337 748 (5.5) 576 503 (8.2) 505 278 (4.7)
UCLA Health 24 312 (3.8) 55 707 (6.9) 107 071 (9.3) 100 786 (5.4)
CKD by 2 eGFR measuresb
PSJH and UCLA Health,
No. (%)
87 225 (30.3) 258 130 (28.3) 238 750 (22.2) 420 678 (26.1)
Adjusted, % 20.8 22.6 21.2 22.6
Diagnosis code, No. (%) 2766 (3.2) 65 213 (25.3) 124 897 (52.3) 171 011 (40.7)
PSJH, No. (%) 64 090 (32.1) 233 369 (28.8) 205 427 (22.9) 363 365 (26.8)
Adjusted % 21.2 23.2 21.7 23.2
Diagnosis code, No. (%) 2287 (3.6) 56 631 (23.9) 105 447 (51.3) 144 956 (39.9)
UCLA Health, No. (%) 23 135 (26.1) 24 734 (13.7) 33 323 (18.3) 57 313 (22.3)
Adjusted % 19.2 19.6 18.8 20.0
Diagnosis code, No. (%) 479 (2.1) 8582 (34.7) 19 450 (58.4) 26 055 (45.5)
CKD by 1 eGFR measure
PSJH and UCLA Health,
No. (%)
170 813 (29.6) 473 685 (31.6) 526 793 (27.8) 873 642 (34.4)
Adjusted % 22.3 27.8 28.5 32.9
Diagnosis code, No. (%) 3304 (1.9) 81 309 (17.2) 193 927 (36.8) 240 630 (27.5)
PSJH, No. (%) 127 351 (29.6) 427 642 (32.4) 458 334 (29.0) 751 690 (35.5)
Adjusted % 21.8 28.8 29.4 34.0
Diagnosis code, No. (%) 2732 (2.1) 69 985 (16.4) 161 180 (35.2) 200 061 (26.6)
UCLA Health, No. (%) 43 362 (29.4) 46 043 (25.7) 68 459 (22.0) 121 952 (28.6)
Adjusted % 23.3 22.6 24.2 27.5
Diagnosis code, No. (%) 572 (1.3) 11 324 (24.6) 32 747 (47.8) 40 569 (33.2)
Abbreviations: CKD, chronic kidney disease; CURE-
CKD, Center for Kidney Disease Research, Education,
and Hope; eGFR, estimated glomerular filtration rate;
PSJH, Providence St Joseph Health; UCLA, University
of California, Los Angeles.
a P < .001 for all unadjusted and adjusted
comparisons.
b Calculated by CKD-Epidemiology equation from the
mean of at least 2 serum creatinine measurements at
least 90 days apart.
JAMANetworkOpen | Nephrology Clinical Characteristics of and Risk Factors for Chronic Kidney Disease
JAMA Network Open. 2019;2(12):e1918169. doi:10.1001/jamanetworkopen.2019.18169 (Reprinted) December 20, 2019 7/14
Downloaded From: https://jamanetwork.com/ by a University of California - Los Angeles User  on 12/20/2019
Temporal trends in CKD prevalence were determined for the 3 following periods: 2006 to
2009, 2010 to 2013, and 2014 to 2017. CKD prevalence rates by CURE-CKD registry criteria increased
over time (2006-2009, 93 644 of 6011 129 [1.6%]; 2010-2013, 393 455 of 6 903084 [5.7%]; and
2014-2017, 683 574 of 8 179 860 [8.4%]). Prevalence rates adjusted for age, sex, and race/ethnicity
and based on eGFR classification alone were higher and stable over time among patients with 2 or
more eGFRmeasurements at least 90 days apart (20.8%, 22.6%, and 21.2%, respectively), while
increasing adjusted prevalence was observed among patients with 1 eGFRmeasurement (22.3%,
27.8%, and 28.5%, respectively). Rates of administrative coding for CKD increased progressively at
both PSJH and UCLA Health (Table 3). For example, among patients with 2 eGFR measurements of
less than 60mL/min/1.73 m2 at least 90 days apart, 2766 of 87 225 (3.2%) were identified by
administrative code during 2006 to 2009 and 124 897 of 238 750 (52.3%) were identified by
administrative code during 2014 to 2017. When CKD categories were analyzed by at least 2 eGFR
measurements at least 90 days apart, unadjusted prevalence rates and prevalence rates adjusted by
age, sex, and race/ethnicity showed progressive increases for categories 3a and 3b with declines in
categories 4 and 5 (eg, category 3a: 2006-2009, 22 805 [prevalence, 26.1%; adjusted prevalence
26.1%]; 2014-2017, 96 449 [prevalence 40.4%; adjusted prevalence, 38.2%]; category 4: 2006-
2009, 22 338 [prevalence, 25.7%, adjusted prevalence, 19.4%], 2014-2017, 42065 [prevalence,
17.6%; adjusted prevalence, 16.1%]) (Figure 1).
PrescriptionMedication Use and Temporal Trends in AdultsWith CKD
Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were
prescribed to 127 574 adults (20.5%) with CKD, with slightly higher use of these agents among those
with CKD and hypertension (112 449 of 434 657 [25.9%]) (eTable 5 in the Supplement). By contrast,
204 307 participants (33.7%) with CKD had prescriptions for nonsteroidal anti-inflammatory drugs
(NSAIDs) or proton pump inhibitors (PPIs). Statins and aspirin were prescribed to 107 445 (17.7%)
and 110 335 (18.2%) individuals, respectively. The most commonly prescribed antihyperglycemic
agents among patients with CKD and diabetes or prediabetes were insulin (38 278 [10.0%]),
metformin (30 393 [7.9%]), and sulfonylureas (16 989 [4.4%]). Medications prescribed among the
cohort of participants at risk of CKD were generally similar to the CKD cohort, except for more
common use of insulin (83 363 [16.3%]) among thosewith diabetes and of NSAIDs (701 493 [35.5%])
and PPIs (295 804 (15.0%]) overall (eTable 6 in the Supplement).
Temporal trends in prescriptionmedications were determined for participants with CKD
determined by 2 eGFRmeasurements of less than 60mL/min/1.73 m2 at least 90 days apart for the
3 periods. Use rates of ACE inhibitors, ARBs, NSAIDs, and PPIs across CKD categories 3a to 5 all
Figure 1. Prevalence of Chronic Kidney Disease (CKD) Category 3a, 3b, 4, and 5 in 2006 to 2009, 2010 to 2013, and 2014 to 2017
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increased (ACE inhibitors: 2006-2009, 5654 [2.0%]; 2010-2013, 46 921 [5.1%]; 2014-2017, 81 601
[7.6%]; ARBs: 2006-2009, 2461 [0.9%]; 2010-2013, 21 791 [2.4%]; 2014-2017, 47 233 [4.4%];
NSAIDs: 2006-2009, 7009 [2.4%]; 2010-2013, 57 705 [6.3%]; 2014-2017, 113 251 [11.0%]; PPIs:
2006-2009, 5331 [1.8%]; 2010-2013, 44 362 [4.9%]; 2014-2017, 83 340 [7.7%]) (Figure 2). Sodium-
glucose cotransporter 2 inhibitors were rarely prescribed, but use increased over time (2006-2009,
0; 2010-2013, 22 [0.002%]; 2014-2017, 1002 [0.093%]).
Discussion
More than 2.6million adults and children who received care at PSJH and UCLA Health from 2006 to
2017 had CKD or were at risk of CKD. Overall, CKD prevalence among adults in the health care
systems was 4.8%, as determined by a combination of eGFR, albuminuria and proteinuria measures,
and administrative code criteria. However, adult CKD prevalence adjusted for age, sex, and race/
ethnicity was 22.6% based on persistently low eGFR alone. Adults with CKDweremore likely to be
older, women, and non-Latino white individuals. In this study, CKD category 3 was most frequent,
with a clear drop-off in prevalence at more advanced categories. Kidney protective agents (ie, renin-
angiotensin system inhibitors) were prescribed to approximately one-fifth of adults with CKD,while
potential nephrotoxins (ie, NSAIDs and PPIs) were prescribed to more than one-third of adults with
CKD. Albuminuria and proteinuria testing for CKD assessment was rarely reported.
The CURE-CKD registry is among themost comprehensive CKD registries worldwide. A unique
feature is the extensive amount of patient-level data on laboratory measures, prescriptions, and vital
signs, combined with administrative codes, to identify CKD andmajor risk factors according to
guideline-based criteria.21,24,25 Previous registries were restricted by containing primarily
administrative data, ESKD, primary care practices, single health care systems, older adults, or
men.4,26-32 In contrast, CURE-CKD participants represent the life span, from children to adults, and
include women andmen and a wide spectrum of races and ethnicities across an expansive region of
thewestern United States that has not been previously involved in large-scale epidemiologic studies
of CKD. Moreover, PSJH and UCLA Health care for patients in a variety of settings that include
academic, primary care, and specialty practices as well as community health and safety-net systems.
Rural patients were well represented in the geography covered by PSJH. Thus, CURE-CKD provides
in-depth identification of patients with and at risk for CKD in contemporary US health care systems.
In CURE-CKD, the progressive increase in adult CKD prevalence was largely driven by diagnostic
coding. Among adults with persistently low eGFR, use of CKD administrative codes increased from
3.2% to 52.3% between the periods of 2006 to 2009 and 2014 to 2017, while overall CKD
prevalence estimates, adjusted for age, sex, and race/ethnicity, were essentially stable between
Figure 2. Prevalence of PrescriptionMedication Use in Chronic Kidney Disease Categories 3a to 5 in 2006
to 2009, 2010 to 2013, 2014 to 2017
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20.8% and 22.6%. Although the upward trend in CKD recognition represents a clinically meaningful
improvement, nearly one-half of patients with low eGFR remained undiagnosed in themost recent
period. The present findings from CURE-CKD point to the critical need for quality improvement and
research at the point of care.
Although nearly two-thirds of the adults with CKD had diabetes, hypertension, or prediabetes,
rates of laboratory testing for albuminuria or proteinuria and of prescribing ACE inhibitors or ARBs
were low. Potentially nephrotoxic agents (ie, NSAIDs and PPIs) were used more commonly than
renin-angiotensin system inhibitors. Given themost common cause of death in CKD is cardiovascular
disease, the low use of preventive agents, such as statins and aspirin, is also concerning.33,34
Compared with participants in the National Health and Nutrition Examination Survey, patients with
CKD in CURE-CKD received ACE inhibitors or ARBs much less often during approximately the same
period.35 Although CURE-CKD found an increase in uptake of renin-angiotensin system inhibitors in
adults with CKD categories 3a to 5, NSAID and PPI use also increased over time. However, these
prescription rates were lower than in the overall CKD cohort, perhaps because of concerns about
adverse effects withmore advanced CKD.While thismay seem counterintuitive for renin-angiotensin
system inhibitors, these agents may be avoided because of fear of complications such as
hyperkalemia or acute kidney injury, especially in acute care settings. In Ontario, Canada, primary
care practices reported ACE inhibitor or ARB use in three-fourths of patients with CKD, but themetric
was confined to thosewith diabetes and albuminuria or adults older than 66 years.30,31 Nevertheless,
rates of albuminuria testing in the overall CKD populationwere comparably low, although avoidance
of NSAIDs was better among patients in Canada than in CURE-CKD.30 A recent Canada-wide study32
from an EHR-based surveillance system in primary care found that only 4 of 12 quality indicators for
CKD care were met, with ACE inhibitor or ARB use among approximately one-third of patients with
diabetes or proteinuria. Contrasts exist between reports from health care systems, community
screenings, primary care practices, and countries, but they consistently illuminate major gaps in CKD
care and the need for more comprehensive surveillance to uncover actionable trends.
In comparison with patients treated at PSJH and UCLA Health, the Kidney Early Evaluation
Program and the National Health and Nutrition Examination Survey have reported lower frequencies
of individuals at risk for CKD in community screenings.36Moreover, associations between risk factors
and CKD are remarkably complex. For example, although a primary contributor to CKD is diabetes,
CKD in patients with diabetes greatly amplifies cardiovascular risks.37 Additionally, nearly one-fifth of
patients with CKD in the CURE-CKD registry had prediabetes. The prediabetes phenotype of CKD
appears less severe than the diabetes phenotype of CKD, as reflected by fewer patients with
advanced CKD categories, albuminuria, or proteinuria and prediabetes. Nevertheless, consistent
with findings from the National Health and Nutrition Examination Survey, findings from CURE-CKD
support the observation that subdiabetic hyperglycemia may contribute to kidney damage before
overt diabetes ensues.13 The CURE-CKD registry contains abundant longitudinal data that will be
invaluable for elucidating CKD incidence among individuals at risk as well as progression and
complications in those with CKD. Given its vast scope, CURE-CKD is also ideally suited to generate
and validate CKD risk predictionmodels.38
Strengths and Limitations
Strengths of the CURE-CKD registry include the large sample size, long observation duration, and
curated patient-level data from 2 US health care systems. However, this study has limitations. First,
CURE-CKD is limited by differences in documentation methods across and between health care
systems and varying attrition rates based on insurance, socioeconomic factors, and geolocation.
Variation in platforms even within a common EHR system also presents a limitation to the creation of
interinstitutional registries, highlighting the importance of collaboration in identifying data elements,
structures, and synchronization. Lack of information on over-the-counter medications
underestimates the usage rates for NSAIDs, PPIs, and other potential nephrotoxins. Data in
CURE-CKD on sodium-glucose cotransporter 2 inhibitor use, recently recommended for diabetes and
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CKD, came from an era before this new indication. It will be important to follow this trend to ensure
sodium-glucose cotransporter 2 inhibitors are delivered to patients who may benefit. Another
limitation of EHR-based registries is undercoding andmiscoding. Tomitigate this limitation, patient-
level data for laboratory values, vital signs, and prescriptionswere used to classify CURE-CKD registry
participants and their care, which allowed for the use of guideline-based criteria for persistence of
low eGFR or elevated albuminuria or proteinuria levels. Although CURE-CKD produced a lower range
estimate of overall CKD prevalence compared with other US reports, this prevalence rate is similar
to that found in Canadian primary care.4,32 A higher range estimate for CKD based solely on eGFR
could be because of more frequent testing in patients with higher risk who were treated by both
specialty and primary care practices at PSJH and UCLA Health. Ascertainment bias is an inherent
limitation of EHR-based registries, and information about CKDwill also bemissed from patients
receiving care elsewhere or not receiving testing. The actual prevalence of overall CKD likely lies
between the low (4.8%) and high (22.6%) range estimations from CURE-CKD. Nevertheless, these
detailed prevalence estimates are strengths that represent the complexity and composition of
patients treated in typical US health care systems.
Conclusions
In conclusion, the CURE-CKD registry reveals a burgeoning number of patients with CKD andmajor
risk factors of diabetes, hypertension, and prediabetes. Rates of identification and use of kidney
protective agents were low, while nephrotoxin use was widespread, underscoring the pressing need
for practice-based improvement in CKD prevention, recognition, and treatment. These real-world
data lay the groundwork for the development of more effective strategies to deliver care that
enhances wellness and survival for patients with and at risk for CKD.
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